FOSCARNET PRESCRIBING INFORMATION PDF

0 Comments

are concise point-of-care prescribing, dosing and administering information to Prior to the initial foscarnet infusion, establish diuresis by administering Prehydrate with mL NS or D5W before first infusion to decrease risk for nephrotoxicity. See prescribing information for dose adjustments for CrCl < Group: antiviral. Solution for injection, 24 mg/ml ml, ml [non-EDL]. General information. Foscarnet is a non-nucleoside pyrophosphate analogue given.

Author: JoJora Dibei
Country: Sudan
Language: English (Spanish)
Genre: Sex
Published (Last): 20 November 2016
Pages: 278
PDF File Size: 15.34 Mb
ePub File Size: 3.1 Mb
ISBN: 379-4-78835-773-5
Downloads: 67954
Price: Free* [*Free Regsitration Required]
Uploader: Fejinn

Major When possible, avoid concurrent use of foscarnet with other drugs foscanet to prolong the QT interval, such as citalopram. Dimethyl sulfoxide Foscarnet may decrease the excretion rate of Dimethyl sulfoxide which prescrkbing result in a higher serum level. Aceprometazine The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Aceprometazine. Prochlorperazine is associated with a possible risk for QT prolongation.

Limited data are available regarding the safety of maprotiline in combination with other QT-prolonging drugs. In addition, there are postmarketing reports of TdP. Moderate Drugs that alter renal function such as foscarnet may alter telbivudine plasma concentrations because telbivudine is eliminated primarily by renal excretion.

The rate of infusion of foscarnet is critical to disturbances in the homeostasis of some serum presribing cations.

Individually dispensed doses of foscarnet should be aseptically transferred and diluted with equal parts of 0. Proarrhythmic foscarnett should be anticipated after initiation of therapy and after each upward dosage adjustment.

Related Posts  ASCEND SMSF PDF

Any unused medicinal product or waste material should be disposed of in accordance with local requirements. Haloperidol The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Haloperidol. Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as maprotiline. Find out more here.

Foscavir 24 mg/ml Solution for Infusion

Formestane Foscarnet may decrease the excretion rate of Formestane which could result in a higher serum level. Dexbrompheniramine The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Foscarnet. Clarithromycin is also associated with an established risk for QT prolongation and TdP.

Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as long-acting beta-agonists. Methotrexate Foscarnet may prescribinv the nephrotoxic activities of Methotrexate. Disopyramide administration is also associated with QT prolongation and TdP. Crizotinib has been associated with concentration-dependent QT prolongation.

In vitro, foscarnet inhibits replication of the herpes simplex virus HSV infotmation, varicella-zoster, Epstein-Barr virus, human herpesvirus 6, and cytomegalovirus. Efavirenz; Lamivudine; Tenofovir Disoproxil Fumarate: Major When possible, informatkon concurrent use of foscarnet with other drugs known to prolong the QT interval, such as tolterodine.

Proglumetacin The risk or severity of nephrotoxicity can be increased when Proglumetacin is combined with Foscarnet. Concurrent administration of other nephrotoxic drugs during treatment with foscarnet i. Domperidone The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Domperidone. Bortezomib The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Foscarnet.

Related Posts  KRAMER VP-725DSA PDF

Foscarnet – DrugBank

Esmolol The risk or severity of QTc prolongation can be increased when Esmolol is combined peescribing Foscarnet. Methylnaltrexone Foscarnet may decrease the excretion rate of Methylnaltrexone which could result in a higher serum level.

Cefoxitin The risk or severity of nephrotoxicity can be increased when Cefoxitin is combined with Foscarnet. Renal pain, renal tubular acidosis, crystal nephropathy, haematuria. Aripiprazole The risk or severity of QTc prolongation ingormation be increased when Foscarnet is combined with Aripiprazole. Gallopamil The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Gallopamil. Piromidic acid The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Piromidic acid.

Cellular DNA polymerases are not affected. Major The risk of renal toxicity may infomration increased if foscarnet is used in conjunction with other nephrotoxic agents such as parenteral vancomycin. However, the data was insufficient to define the potential teratogenicity of foscarnet in humans at the dosages used. Salbutamol Foscarnet may decrease the excretion rate of Salbutamol which could result in a higher serum level.